Skip to main content

Advertisement

Log in

Tadalafil in the treatment of erectile dysfunction

  • Published:
Current Urology Reports Aims and scope Submit manuscript

Abstract

Oral phosphodiesterase-5 inhibitors have emerged as the preferred first-line treatment for erectile dysfunction worldwide because of patient convenience, efficacy, and safety. Clinical trials have shown that tadalafil significantly enhances erectile function across a wide range of etiologies and provides a prolonged period of effectiveness independent of food or alcohol. In this review, the pharmacokinetic and pharmacodynamic characteristics, efficacy, and safety of tadalafil are discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. McKinlay JB: The worldwide prevalence and epidemiology of erectile dysfunction. Int J Impot Res 2000, 12(suppl 4):S6-S11.

    Article  PubMed  Google Scholar 

  2. Canadian Urological Association Guidelines Committee: Erectile dysfunction practice guidelines. Can J Urol 2002, 9:1583–1587.

    Google Scholar 

  3. Brock GB, McMahon CG, Chen KK, et al.: Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analysis. J Urol 2002, 168:1332–1336. Integrated analysis of efficacy and safety of tadalafil based on five randomized, double-blind, placebo-controlled trials enrolling 1112 men.

    Article  PubMed  CAS  Google Scholar 

  4. Saenz de Tajada I: Nitric oxide as a mediator of relaxation of the corpus cavernosum. N Engl J Med 1992, 326:1638.

    Google Scholar 

  5. Lincoln TM, Cornwell TL: Towards an understanding of the mechanism of action of cyclic AMP and cyclic GMP in smooth muscle relaxation. Blood Vessels 1991, 28:129–137.

    PubMed  CAS  Google Scholar 

  6. Beavo JA: Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 1995, 75:725–748.

    PubMed  CAS  Google Scholar 

  7. Boolell M, Allen MJ, Ballard SA, et al.: Sildenafil: an orally active Type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 1996, 8:47–52.

    PubMed  CAS  Google Scholar 

  8. Uckert S, Kuth A, Stief CG, Jonas U: Phosphodiesterase isoenzymes as pharmacologic targets in the treatment of male erectile dysfunction. World J Urol 2001, 19:14–22.

    Article  PubMed  CAS  Google Scholar 

  9. Lincoln TM: Cyclic GMP and mechanisms of vasodilation. Pharmacol Ther 1989, 41:479–502.

    Article  PubMed  CAS  Google Scholar 

  10. Saenz de Tajada I: Molecular mechanisms for the regulation of penile smooth muscle contractility. Int J Impot Res 2000, 12(suppl 4):S34-S38.

    Article  Google Scholar 

  11. Patterson B, Bedding A, Jewell H, et al.: Dose-normalized pharmacokinetics of single-dose tadalafil (IC351) in healthy volunteers (Abstract 14). Int J Impot Res 2001, 13(suppl 5):S63.

    Google Scholar 

  12. Eardley I, Cartledge J: Tadalfil (Cialis) for men with erectile dysfunction. Int J Clin Pract 2002, 56:300–304.

    PubMed  CAS  Google Scholar 

  13. Krane R, Brock G, Earley I, et al.: Oral non-endocrine treatment. In Erectile Dysfunction. Edited by Jardin A, Wagner G, Khoury S, et al. Plymouth UK: Health Publication Ltd; 2000:241–278.

    Google Scholar 

  14. Pryor J: Vardenafil: update on clinical experience. Int J Impot Res 2002, 14(suppl 1):S65-S69.

    Article  PubMed  Google Scholar 

  15. Saenz de Tejada I, Angulo J, Gadau M, Florio V: Comparative selectivity profiles of tadalafil, sildenafil, and vardenafil using in vitro phosphodiesterase activity assay. Int J Imp Res 2002, 14(suppl 4):S20-S32.

    Google Scholar 

  16. Montorsi F, McDermott TE, Morgan R, et al.: Efficacy and safety of fixed-dose oral sildenafil in treatment of erectile dysfunction of various etiologies. Urology 1999, 55:1011–1018.

    Article  Google Scholar 

  17. Goldstein I, Lue TF, Padma-Nathan H, et al.: Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998, 338:1397–1404.

    Article  PubMed  CAS  Google Scholar 

  18. Porst H, Rosen R, Padma-Nathan H, et al.: The efficacy and tolerability of vardenafil, a new, oral selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Int J Impot Res 2001, 13:192–199.

    Article  PubMed  CAS  Google Scholar 

  19. Brock GB: Oral agents: first-line therapy for erectile dysfunction. Eur Urol 2002, 1(suppl):12–18.

    CAS  Google Scholar 

  20. Patterson B, Bedding A, Jewell H, et al.: The effect of intrinsic and extrinsic factors on the pharmacokinetic properties of tadalafil (ICI351) (Abstract 16). Int J Impot Res 2001, 13(suppl 5):S62.

    Google Scholar 

  21. Rosen RC, Riley A, Wagner G, et al.: The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997, 49:822–830.

    Article  PubMed  CAS  Google Scholar 

  22. Rosen RC, Cappelleri JC, Gendrano N: The International Index of Erectile Function (IIEF): a state-of-the-science review. Int J Impot Res 2002, 14:226–244.

    Article  PubMed  CAS  Google Scholar 

  23. Cappelleri JC, Rosen RC, Smith MD, et al.: Diagnostic evaluation of the erectile function domain of the International Index of Erectile Dysfunction. Urology 1999, 54:346–351.

    Article  PubMed  CAS  Google Scholar 

  24. Romeo JH, Seftel AD, Madhun ZT, Aron DC: Sexual function in men with diabetes type 2: association with glycemic control. J Urol 2000, 163:788–791.

    Article  PubMed  CAS  Google Scholar 

  25. Metro MJ, Broderick GA: Diabetes and vascular impotence: Does insulin dependence increase the relative severity? Int J Impot Res 1999, 11:87–89.

    Article  PubMed  CAS  Google Scholar 

  26. Saenz deTejada I, Anglin GT, Knight JR, Emmick JT: Effects of tadalafil on erectile dysfunction in men with diabetes. Diabetes Care 2002, 25:2159–2164. Randomized, multicenter, placebo-controlled trial investigating the efficacy and safety of tadalafil in a population of 216 diabetic men.

    Article  Google Scholar 

  27. Padma-Nathan H, Rosen RC, Shabsigh R, et al.: Tadalafil (IC351) provides prompt and extended period of response for the treatment of men with ED (Abstract 20). Int J Impot Res 2001, 13(suppl 5):S64.

    Google Scholar 

  28. Porst H, Rosen RC, Padma-Nathan H, et al.: Tadalafil allows men with erectile dysfunction to have successful intercourse up to 36 hours postdose (Abstract 709). J Urol 2002, 167:177.

    Article  Google Scholar 

  29. Porst H, Padma-Nathan H, Giuliano F, et al.: Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial. Urology 2003, 62:121–126.

    Article  PubMed  Google Scholar 

  30. Emmick JT, Stuewe SR, Mitchell M: Overview of cardiovascular effects of tadalafil. Eur Heart J 2002, 4(suppl):H32-H47.

    CAS  Google Scholar 

  31. Kloner RA, Watkins VS, Costigan TM, et al.: Cardiovascular profile of tadalafil, a new PDE5 inhibitor (Abstract 707). J Urol 2002, 167:176.

    Google Scholar 

  32. Hellstrom WJ, Overstreet JW, Yu A, et al.: Tadalafil has no detrimental effect on human spermatogenesis or reproductive hormones. J Urol 2003, 170:887–891.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bella, A.J., Brock, G.B. Tadalafil in the treatment of erectile dysfunction. Curr Urol Rep 4, 472–478 (2003). https://doi.org/10.1007/s11934-003-0029-8

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11934-003-0029-8

Keywords

Navigation